Comparative effect of candesartan and amlodipine, and effect of switching from valsartan, losartan, telmisartan and olmesartan to candesartan, on early morning hypertension and heart rate

References

• Nippon Data 80 Research Group. Impact of elevated blood pressure on mortality from all causes, cardiovascular diseases, heart disease and stroke among Japanese: 14 year follow-up of randomly selected population from Japanese-Nippon data 80. J Hum Hypertens. 2003;17:851–857.
   PubMed Web of Science ®Google Scholar
• Lawes CM, Rodgers A, Bennett DA, Parag V, Suh I, Ueshima H, et al. Asia Pacific Cohort Studies Collaboration. Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens. 2003;21:707–716.
   PubMed Web of Science ®Google Scholar
• Niiranen TJ, Hanninen MR, Johansson J, Reunaen A, Jula AM. Home-measured blood pressure is a stronger predictor of cardiovascular risk than office blood pressure: The Finn-Home study. Hypertension. 2010;55:1346–1351.
   PubMed Web of Science ®Google Scholar
• Muller JE, Stone PH, Turi ZG, Zoltan G, Rutherford JD, Czeisler CA, et al. Circadian variation in the frequency of onset of acute myocardial infarction. N Eng J Med. 1985;313:1315–1322.
   PubMed Web of Science ®Google Scholar
• Elliot WJ. Circadian variation in the timing of stroke onset: A meta-analysis. Stroke. 1998;29:992–996.
   PubMed Web of Science ®Google Scholar
• Muller JE, Ludmer PL, Willich SN, Tofler GH, Aymer G, Klangos I, et al. Circadian variation in the frequency of sudden cardiac death. Circulation. 1987;75:131–138.
   PubMed Web of Science ®Google Scholar
• Palatini P, Casiglia E, Julius S, Pessina AC. High heart rate: A risk factor for cardiovascular death in elderly men. Arch Intern Med. 1999;159:585–592.
   PubMed Web of Science ®Google Scholar
• Thomas F, Bean K, Provost JC, Guize L, Benetos A. Combined effects of heart rate and pulse pressure on cardiovascular mortality according to age. J Hypertens. 2001;19:863–869.
   PubMed Web of Science ®Google Scholar
• Hozawa A, Ohkubo T, Kikuya M, Ugajin T, Yamaguchi J, Asayama K, et al. Am J Hypertens. 2005;18:477–485.
   Google Scholar
• Japanese Society of Hypertension (JSH) guidelines for self-monitoring of blood pressure at home.
   Google Scholar
• Elliot HL, Green ST, Vincent J, Meredith PA. An assessment of the pharmacokinetics and pharmacodynamics of single doses of amlodipine in elderly normotensives. Pharmacol Res. 1992;26:33–39.
   PubMed Web of Science ®Google Scholar
• Hubner R, Hogemann AM, Sunzel M, Riddell JG. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. J Hum Hypertens. 1997:11 Suppl 2:S19–25.
   PubMed Web of Science ®Google Scholar
• Vanderheyden PM, Fierens FL, De Backer J, Vauquelin G. Reversible and syntopic interaction between angiotensin receptor antagonists on Chinese hamster ovary cells expressing human angiotensin II type 1 receptors. Biochem Pharmacol. 2000;59:927–935.
   PubMed Web of Science ®Google Scholar
• Ojima M, Inada Y, Shibouta Y, Wada T, Sanada T, Kubo K, et al. Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor. Eur J Pharmacol. 1997;319: 137–146.
   PubMed Web of Science ®Google Scholar
• Kiya Y, Miura S, Matsuo Y, Karnik SS, Saku K. Abilities of candesartan and other AT1 receptor blockers to impair angiotensin II-induced AT1 receptor activation after wash-out. J Renin Angiotensin Aldosterone Syst. 2012;13:76–83.
   PubMed Web of Science ®Google Scholar
• Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation. 1989;79:733–743.
   PubMed Web of Science ®Google Scholar
• Muller JE, Ludmer PL, Willich SN, Tofler GH, Ayler G, Klangos I, et al. Circadian variation in the frequency of sudden cardiac death. Circulation. 1987;75:131–138.
   PubMed Web of Science ®Google Scholar
• Kawano Y, Tochikubo O, Minamisawa K, Miyajima E, Ishii M. Circadian variation of haemodynamics in patients with essential hypertension: Comparison between early morning and evening. J Hypertens. 1994;12:1405–1412.
   PubMed Web of Science ®Google Scholar
• Lindqvist M, Kahan T, Melcher A, Ekholm M, Hjemdahl P. Long-term calcium antagonist treatment of human hypertension with mibefradil or amlodipine increases sympathetic nerve activity. J Hypertension. 2007;25:169–175.
   PubMed Web of Science ®Google Scholar
• Dendorfer A, Raasch W, Tempel K, Dominiak P. Comparison of the vascular and antiadrenergic activities of four angiotensin II type 1 antagonists in the pithed rat. J Hypertens. 2002;20:1151–1156.
   PubMed Web of Science ®Google Scholar
• Ogihara T, Nakao K, Fukui T, Fukiyama K, Ueshima K, Oba K, et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: Candesartan Antihypertensive Survival Evaluation in Japan trial. Hypertension. 2008;51:393–398.
   PubMed Web of Science ®Google Scholar
• Matsuno Y, Minatoguchi S, Fhujiwara H, GIFU Substudy Group of The Case-J Trial. Effects of candesartan versus amlodipine on home-measured blood pressure, QT dispersion and left ventricular hypertrophy in high-risk hypertsnsive patients. Blood Press. 2011;Suppl 1:12–19.
   Google Scholar
• Lo MW, Goldberg MR, McCrea JB, Lu H, Furtek CI, Bjomsson TD. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther. 1995;58:641–649.
   PubMed Web of Science ®Google Scholar
• Muller P, Flesch G, de Gasparo M, Gasparini M, Howald H. Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects. Eur J Clin Pharmacol. 1997;52: 441–449.
   PubMed Web of Science ®Google Scholar
• Stangier J, Su CA, Roth W. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J Int Med Res. 2000;28:149–167.
   PubMed Web of Science ®Google Scholar
• Schwocho LR, Masonson HN. Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects. J Clin Pharmacol. 2001;41:515–527.
   PubMed Web of Science ®Google Scholar
• Bhuiyan MA, Ishiguro M, Hossain M, Nakamura T, Ozaki M, Miura S, et al. Binding sites of valsartan, candesartan and losartan with angiotensin II receptor 1 subtype by molecular modeling. Life Sci. 2009;85:136–140.
   PubMed Web of Science ®Google Scholar
• Van Liefde I, Vauquelin G. Sartan-AT1 receptor interactions: In vitro evidence for insurmountable antagonism and inverse agonism. Mol Cell Endocrinol. 2009;302:237–243.
   PubMed Web of Science ®Google Scholar
• Metoki H, Ohkubo T, Kikuya M, Asayama K, Obara T, Hashimoto J, et al. Prognostic significance for stroke of a morning pressor surge and a nocturnal blood pressure decline: The Ohasama Study. Hypertension. 2006;47: 149–154.
   PubMed Web of Science ®Google Scholar
• Li Y, Thijs L, Hansen TW, Kikuya M, Boggia J, Richart T, et al. Prognostic value of the morning blood pressure surge in 5645 subjects from 8 populations. Hypertension. 2010;55: 1040–1048.
   PubMed Web of Science ®Google Scholar